Recent News

• 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.04.2025 - 2025 Wells Fargo Healthcare Conference
• 09.03.2025 - Citi’s 2025 Biopharma Back to School Conference
• 08.25.2025 - Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
• 08.25.2025 - Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
• 08.14.2025 - Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
• 08.14.2025 - Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
• 08.05.2025 - Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
• 08.05.2025 - Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
• 06.13.2025 - Beam Therapeutics Investor Webcast – EHA 2025

Recent Filings

• 08.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.06.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2025 - 8-K Current report
• 08.05.2025 - EX-99.1 EX-99.1
• 08.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 8-K Current report
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities